Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Ascites 1

Interventions

Cisplatin 3pembrolizumab 2amminedichloro(2-methylpyridine)platinum(II) 2Nivolumab 2Cytoreduction Surgical Procedures 2trastuzumab deruxtecan 1trametinib 1sodium thiosulfate 1pertuzumab 1pazopanib 1osimertinib 1motexafin gadolinium 1fludarabine 1danvatirsen 1dabrafenib 1cobimetinib 1cemiplimab 1alectinib 1aldesleukin 1X-Rays 1Ritonavir 1Remote Patient Monitoring 1Patient-Specific Modeling 1Pafolacianine 1Oxaliplatin 1Observation 1Mitomycin 1Microscopy, Electron 1Itraconazole 1Hyperthermic Intraperitoneal Chemotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × danvatirsen × Gynecologic × Clear all
NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
1 enrolled 10 charts
GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡